Form 4: Armata Pharmaceuticals Executive Pierre Kyme Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Chief Business Officer Pierre Kyme of Armata Pharmaceuticals reports disposing of 1,027 shares to cover income tax obligations related to restricted stock units.
Summary
- On March 14, 2025, Pierre Kyme, Chief Business Officer of Armata Pharmaceuticals, disposed of 1,027 shares of common stock.
- The transaction was executed to cover income tax and withholding remittance obligations related to the net settlement of restricted stock units.
- The shares were disposed of at a price of $1.95 per share.
- Following the transaction, Kyme directly owns 10,491 shares of Armata Pharmaceuticals.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports a routine transaction related to tax obligations.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of stock disposal transaction |
| 04/25/2025 | Date of signature on the Form 4 filing |
Keywords
Form 4, Armata Pharmaceuticals, Pierre Kyme, Stock Disposal, Restricted Stock Units, Tax Obligations, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.